- Published at
- by gurufocus.com
negative
negative
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients | RHHBY Stock News
Roche (RHHBY) halts Elevidys dosing for non-ambulatory Duchenne muscular dystrophy patients due to safety concerns. Two fatal acute liver failure cases